| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/17/2011 | US20110064753 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 03/17/2011 | US20110064752 Extracellular targeted drug conjugates |
| 03/17/2011 | US20110064751 Targeted immunoconjugates |
| 03/17/2011 | US20110064750 Method and kit for treating nicotine addiction |
| 03/17/2011 | US20110064749 Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| 03/17/2011 | US20110064748 Pharmaceutical combination and method for treating tumor |
| 03/17/2011 | US20110064747 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10) |
| 03/17/2011 | US20110064746 Treatment of drug-related side effect and tissue damage by targeting the cd24-hmgb1-siglec10 axis |
| 03/17/2011 | US20110064745 Therapeutic Antibodies, Antibody Fragments And Antibody Conjugates |
| 03/17/2011 | US20110064744 Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| 03/17/2011 | US20110064743 Human anti-cancer antibodies |
| 03/17/2011 | US20110064742 Somatostatin Receptor Antagonists and Glucose Control or Hypoglycemia |
| 03/17/2011 | US20110064741 Stable amyloid beta monomers and oligomers |
| 03/17/2011 | US20110064740 Antigen binding proteins |
| 03/17/2011 | US20110064739 Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung |
| 03/17/2011 | US20110064738 Human anti-vegf polyclonal antibodies and uses thereof |
| 03/17/2011 | US20110064737 ErbB ANTAGONISTS FOR PAIN THERAPY |
| 03/17/2011 | US20110064736 Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| 03/17/2011 | US20110064735 Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| 03/17/2011 | US20110064734 Prevention and treatment of amyloidogenic disease |
| 03/17/2011 | US20110064733 Ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 03/17/2011 | US20110064732 Methods and compositions for diagnostic use in cancer patients |
| 03/17/2011 | US20110064731 Use of IL-20 Antagonists for Treating Rheumatoid Arthritis and Osteoporosis |
| 03/17/2011 | US20110064730 Method of modulating angiogenesis |
| 03/17/2011 | US20110064729 Administration of agents for the treatment of inflammation |
| 03/17/2011 | US20110064728 IL-17 Homologous Polypeptides and Therapeutic Uses Thereof |
| 03/17/2011 | US20110064727 Immunoglobulin Variants Outside the Fc Region |
| 03/17/2011 | US20110064726 ANTI IgE ANTIBODIES |
| 03/17/2011 | US20110064725 High affinity, anti-human ige antibodies |
| 03/17/2011 | US20110064724 Methods for Identifying Compounds for the Treatment of Type 1 Diabetes |
| 03/17/2011 | US20110064723 Formulation for room temperature stabilization of a live attenuated bacterial vaccine |
| 03/17/2011 | US20110064722 Modulators of alpha-synuclein toxicity |
| 03/17/2011 | US20110064721 Cathepsin-d neuroprotection |
| 03/17/2011 | US20110064698 Hepatitis c virus inhibitors |
| 03/17/2011 | US20110064697 Hepatitis c virus inhibitors |
| 03/17/2011 | US20110064693 Antiviral Drugs for Treatment of Arenavirus Infection |
| 03/17/2011 | US20110064692 Human bone-forming cells in the treatment of conditions and bone diseases associated with immunodeficiency or immunosuppression |
| 03/17/2011 | US20110064691 Method to enhance hematopoiesis |
| 03/17/2011 | US20110064689 In situ immunization |
| 03/17/2011 | US20110064676 Diagnostic and therapeutic nanoparticles |
| 03/17/2011 | US20110064675 Elemental iron nanoparticles |
| 03/17/2011 | US20110064665 Diagnostic and therapeutic nanoparticles |
| 03/17/2011 | US20110064664 Methods and compositions involving chitosan nanoparticles |
| 03/17/2011 | US20110064663 Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use |
| 03/17/2011 | US20110064654 Prostate cancer diagnosis and treatment |
| 03/17/2011 | US20110064653 Class I Anti-CEA Antibodies and Uses Thereof |
| 03/17/2011 | CA2774326A1 Modulation of yeast-based immunotherapy products and responses |
| 03/17/2011 | CA2774140A1 Vaccines directed to langerhans cells |
| 03/17/2011 | CA2773690A1 Protein matrix vaccines of improved immunogenicity |
| 03/17/2011 | CA2773637A1 Combination vaccines against respiratory tract diseases |
| 03/17/2011 | CA2773614A1 Method of treating cancer by inhibiting trim59 expression or activity |
| 03/17/2011 | CA2773579A1 Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4) |
| 03/17/2011 | CA2773556A1 Methods for treating psoriasis |
| 03/17/2011 | CA2773486A1 New vaccine formulations comprising saponin-containing adjuvants |
| 03/17/2011 | CA2773426A1 Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| 03/17/2011 | CA2773424A1 Hypoallergenic hybrid polypeptides for the treatment of allergy |
| 03/17/2011 | CA2773236A1 S. aureus allergen |
| 03/17/2011 | CA2773218A1 Use of vap-1 inhibitors for treating fibrotic conditions |
| 03/17/2011 | CA2771863A1 Compositions that induce t cell help |
| 03/17/2011 | CA2771771A1 Porcine torque teno virus vaccines and diagnosis |
| 03/17/2011 | CA2771334A1 Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
| 03/16/2011 | EP2295972A1 S. aureus allergen |
| 03/16/2011 | EP2295606A1 Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 03/16/2011 | EP2295590A1 Nucleic acid sequences encoding proteins capable of associating into a virus-like particle |
| 03/16/2011 | EP2295588A1 Novel artificial antigen presenting cells and uses thefor |
| 03/16/2011 | EP2295578A2 Cyp1b1 nucleic acids and methods of use |
| 03/16/2011 | EP2295575A2 Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| 03/16/2011 | EP2295568A2 Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions |
| 03/16/2011 | EP2295542A1 Rescue of influenza virus |
| 03/16/2011 | EP2295469A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 03/16/2011 | EP2295468A1 Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| 03/16/2011 | EP2295467A1 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 03/16/2011 | EP2295466A2 Antibodies to myostatin |
| 03/16/2011 | EP2295465A2 Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
| 03/16/2011 | EP2295464A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/16/2011 | EP2295463A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/16/2011 | EP2295462A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/16/2011 | EP2295461A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/16/2011 | EP2295460A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/16/2011 | EP2295459A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/16/2011 | EP2295458A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/16/2011 | EP2295457A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/16/2011 | EP2295456A1 Albumin fusion proteins |
| 03/16/2011 | EP2295447A1 GIPs, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding protein |
| 03/16/2011 | EP2295082A1 Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence |
| 03/16/2011 | EP2295081A1 Antibodies to OPGL |
| 03/16/2011 | EP2295080A2 B-cell reduction using CD37-specific and CD20-specific binding molecules |
| 03/16/2011 | EP2295079A2 Method for treating inflammation |
| 03/16/2011 | EP2295078A2 Method for treating inflammation |
| 03/16/2011 | EP2295077A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 03/16/2011 | EP2295076A1 Hypoallergenic hybrid polypeptides for the treatment of allergy |
| 03/16/2011 | EP2295075A1 Enterohemorragic escherichia coli vaccine |
| 03/16/2011 | EP2295074A1 Anti-neovasculature preparations for treating cancer |
| 03/16/2011 | EP2295073A1 Antibody against CD22 for the treatment of tumour of hematopoietic origin |
| 03/16/2011 | EP2295071A1 Low dose methods for treating disorders in which TNF-alpha activity is detrimental |
| 03/16/2011 | EP2295067A1 E-selectin for inducing immunotolerance |
| 03/16/2011 | EP2295065A1 Modified heat shock protein-antigenic peptide complex |
| 03/16/2011 | EP2295064A1 Monoclonal antibody therapy for pancreas cancer |
| 03/16/2011 | EP2295023A1 Flavivirus vaccines |
| 03/16/2011 | EP2294917A1 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |